SIRT1 deficiency increases O-GlcNAcylation of tau, mediating synaptic tauopathy

[1]  Fei Liu,et al.  SIRT1 Regulates Tau Expression and Tau Synaptic Pathology. , 2021, Journal of Alzheimer's disease : JAD.

[2]  Zheng Zhou,et al.  Dendritic/Post-synaptic Tau and Early Pathology of Alzheimer’s Disease , 2021, Frontiers in Molecular Neuroscience.

[3]  Zheng Zhou,et al.  The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[4]  Faraz Ahmad,et al.  Synaptosome as a tool in Alzheimer’s disease research , 2020, Brain Research.

[5]  Fei Liu,et al.  SIRT1 regulates O-GlcNAcylation of tau through OGT , 2020, Aging.

[6]  S. Yu,et al.  Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates δ-Secretase by Upregulating C/EBPβ in Alzheimer’s Disease , 2019, Cell reports.

[7]  Fei Liu,et al.  Pathological Alterations of Tau in Alzheimer’s Disease and 3xTg-AD Mouse Brains , 2019, Molecular Neurobiology.

[8]  A. Ittner,et al.  Dendritic Tau in Alzheimer’s Disease , 2018, Neuron.

[9]  Derek H. Oakley,et al.  Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain , 2018, Front. Neurosci..

[10]  N. Krogan,et al.  SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy , 2018, The Journal of Neuroscience.

[11]  Xiaoyong Yang,et al.  Protein O-GlcNAcylation: emerging mechanisms and functions , 2017, Nature Reviews Molecular Cell Biology.

[12]  Wendy Noble,et al.  Roles of tau protein in health and disease , 2017, Acta Neuropathologica.

[13]  F. Menniti,et al.  NMDA Receptors in the Central Nervous System. , 2017, Methods in molecular biology.

[14]  Xuben Hou,et al.  Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation , 2016, Scientific Reports.

[15]  G. Hart,et al.  Roles of O-GlcNAc in chronic diseases of aging. , 2016, Molecular aspects of medicine.

[16]  S. Walker,et al.  The Biochemistry of O-GlcNAc Transferase: Which Functions Make It Essential in Mammalian Cells? , 2016, Annual review of biochemistry.

[17]  W. Noble,et al.  Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease , 2016, Acta Neuropathologica Communications.

[18]  J. Henley,et al.  Synaptic AMPA receptor composition in development, plasticity and disease , 2016, Nature Reviews Neuroscience.

[19]  T. Cassano,et al.  Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease. , 2016, Pharmacological research.

[20]  T. Okajima,et al.  Intracellular and extracellular O-linked N-acetylglucosamine in the nervous system , 2015, Experimental Neurology.

[21]  M. Murray,et al.  Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease. , 2015, Human molecular genetics.

[22]  J. Saura,et al.  C/EBPβ and C/EBPδ transcription factors: Basic biology and roles in the CNS , 2015, Progress in neurobiology.

[23]  H. Rhim,et al.  Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors , 2015, International journal of molecular sciences.

[24]  Se Jin Park,et al.  Tau Phosphorylation at Serine 396 Residue Is Required for Hippocampal LTD , 2015, The Journal of Neuroscience.

[25]  B. Tang,et al.  SIRT1 in the brain—connections with aging-associated disorders and lifespan , 2015, Front. Cell. Neurosci..

[26]  N. Krogan,et al.  Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits , 2015, Nature Medicine.

[27]  Brian C Coe,et al.  Alzheimer's Disease-Like Pathology Induced by Amyloid-β Oligomers in Nonhuman Primates , 2014, The Journal of Neuroscience.

[28]  D. Vocadlo,et al.  O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond. , 2014, Chemical Society reviews.

[29]  L. Ball,et al.  O-GlcNAc transferase and O-GlcNAcase: achieving target substrate specificity , 2014, Amino Acids.

[30]  R. Huganir,et al.  Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer‐induced AMPA glutamate receptor signaling deficits , 2014, The European journal of neuroscience.

[31]  G. Perry,et al.  Phosphorylation of tau protein at sites Ser396–404 is one of the earliest events in Alzheimer's disease and Down syndrome , 2014, Neuropathology and applied neurobiology.

[32]  L. Guarente,et al.  SIRT1 in Neurodevelopment and Brain Senescence , 2014, Neuron.

[33]  L. Carboni,et al.  Human apolipoprotein E4 modulates the expression of Pin1, Sirtuin 1, and Presenilin 1 in brain regions of targeted replacement apoE mice , 2014, Neuroscience.

[34]  Yong Ryoul Yang,et al.  O-GlcNAcylation in cellular functions and human diseases. , 2014, Advances in biological regulation.

[35]  A. Kossenkov,et al.  O-Linked β-N-Acetylglucosamine (O-GlcNAc) Site Thr-87 Regulates Synapsin I Localization to Synapses and Size of the Reserve Pool of Synaptic Vesicles* , 2013, The Journal of Biological Chemistry.

[36]  G. Donmez,et al.  SIRT1 and SIRT2: emerging targets in neurodegeneration , 2013, EMBO molecular medicine.

[37]  I. Grundke‐Iqbal,et al.  Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. , 2012, Journal of Alzheimer's disease : JAD.

[38]  B. Hyman,et al.  The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. , 2012, The American journal of pathology.

[39]  N. Leclerc,et al.  Interaction of Endogenous Tau Protein with Synaptic Proteins Is Regulated by N-Methyl-d-aspartate Receptor-dependent Tau Phosphorylation* , 2012, The Journal of Biological Chemistry.

[40]  F. LaFerla,et al.  Soluble Aβ promotes wild-type tau pathology in vivo , 2012, Alzheimer's & Dementia.

[41]  A. Burlingame,et al.  Global Identification and Characterization of Both O-GlcNAcylation and Phosphorylation at the Murine Synapse* , 2012, Molecular & Cellular Proteomics.

[42]  Matthew S Macauley,et al.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. , 2012, Nature chemical biology.

[43]  Xiongwei Zhu,et al.  Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy , 2012, International journal of Alzheimer's disease.

[44]  Yan-wen Zhang,et al.  Tau protein is involved in morphological plasticity in hippocampal neurons in response to BDNF , 2012, Neurochemistry International.

[45]  M. Rowan,et al.  Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances , 2012, Pharmacology Biochemistry and Behavior.

[46]  W. Klein,et al.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.

[47]  M. Haigis,et al.  Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases. , 2011, Current pharmaceutical design.

[48]  Jianhua Shi,et al.  Developmental Regulation of Protein O-GlcNAcylation, O-GlcNAc Transferase, and O-GlcNAcase in Mammalian Brain , 2011, Alzheimer's & Dementia.

[49]  H. Braak,et al.  Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? , 2011, Acta Neuropathologica.

[50]  Rudi D'Hooge,et al.  Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant , 2011, The Journal of Neuroscience.

[51]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[52]  Matthew G. Nowak,et al.  Human Alzheimer’s disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry , 2011, Amino Acids.

[53]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[54]  V. Haroutunian,et al.  Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.

[55]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[56]  Lois E. H. Smith,et al.  SIRT1 Is Essential for Normal Cognitive Function and Synaptic Plasticity , 2010, The Journal of Neuroscience.

[57]  L. Tsai,et al.  A novel pathway regulates memory and plasticity via SIRT1 and miR-134 , 2010, Nature.

[58]  D. Vocadlo,et al.  Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes. , 2010, Current signal transduction therapy.

[59]  I. Grundke‐Iqbal,et al.  Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. , 2009, The American journal of pathology.

[60]  Jianhua Shi,et al.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. , 2009, Brain : a journal of neurology.

[61]  Najla Kfoury,et al.  Identification of neuronal target genes for CCAAT/Enhancer Binding Proteins , 2009, Molecular and Cellular Neuroscience.

[62]  D. Bennett,et al.  Sirtuin 1 Reduction Parallels the Accumulation of Tau in Alzheimer Disease , 2009, Journal of neuropathology and experimental neurology.

[63]  G. Hart,et al.  Cross-talk between GlcNAcylation and phosphorylation: Site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc , 2008, Proceedings of the National Academy of Sciences.

[64]  Mark A. Smith,et al.  Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer’s disease , 2008, International journal of experimental pathology.

[65]  G. Perry,et al.  Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology , 2007, Neuropathology and applied neurobiology.

[66]  Karel Svoboda,et al.  Experience-dependent and cell-type-specific spine growth in the neocortex , 2006, Nature.

[67]  Jonathan C Trinidad,et al.  O-Linked N-Acetylglucosamine Proteomics of Postsynaptic Density Preparations Using Lectin Weak Affinity Chromatography and Mass Spectrometry*S , 2006, Molecular & Cellular Proteomics.

[68]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[69]  Wilhelm Haas,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1 , 2005, Nature.

[70]  Steven P Gygi,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. , 2005, Nature.

[71]  M. Bear,et al.  LTP and LTD An Embarrassment of Riches , 2004, Neuron.

[72]  S. Ficarro,et al.  Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Rena Li,et al.  CCAAT/enhancer binding protein δ (C/EBPδ) expression and elevation in Alzheimer’s disease , 2004, Neurobiology of Aging.

[74]  G. Hart,et al.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[75]  L. Guarente,et al.  The Sir2 family of protein deacetylases. , 2004, Annual review of biochemistry.

[76]  Rena Li,et al.  CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. , 2004, Neurobiology of aging.

[77]  Wyeth W. Wasserman,et al.  JASPAR: an open-access database for eukaryotic transcription factor binding profiles , 2004, Nucleic Acids Res..

[78]  H. Kasai,et al.  Structure–stability–function relationships of dendritic spines , 2003, Trends in Neurosciences.

[79]  R. Cole,et al.  Localization of the O-GlcNAc transferase and O-GlcNAc-modified proteins in rat cerebellar cortex , 2003, Brain Research.

[80]  M G McInnis,et al.  Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. , 2000, Science.

[81]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[82]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[83]  P. Coleman,et al.  Reduction of O-Linked N-Acetylglucosamine-Modified Assembly Protein-3 in Alzheimer’s Disease , 1998, The Journal of Neuroscience.

[84]  G. Hart,et al.  The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine* , 1996, The Journal of Biological Chemistry.

[85]  I. Fischer,et al.  Tau Is Enriched on Dynamic Microtubules in the Distal Region of Growing Axons , 1996, The Journal of Neuroscience.

[86]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[87]  J. Trojanowski,et al.  Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau , 1994, Neuron.

[88]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[89]  R. Umek,et al.  Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. , 1991, Genes & development.

[90]  G. Hart,et al.  Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. , 1984, The Journal of biological chemistry.

[91]  S. Yu,et al.  Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates delta-Secretase by Upregulating C/EBP beta in Alzheimer's Disease , 2022 .